Liraglutide Peptide | Pharmaceutical Obesity Treatment
Liraglutide Peptide | Pharmaceutical Obesity Treatment
Obesity Treatment , Liraglutide , Liraglutide Peptide
Product Name: Liraglutide API Powder
Product Purity: ≥98%
CAS No: 204656-20-2
Product Purity: ≥98%
CAS No: 204656-20-2
Send Inquiry
Description
Synthetic Peptide • GLP-1 Receptor AgonistLiraglutide API Powder Supply
High-Purity Metabolic Glucagon-Like Peptide-1 Analogue for Precision Downstream Injection and Weight Management Formulation Lines
Assay ≥ 99.0% (RP-HPLC Purity)
Controlled Endotoxins ≤ 0.5 EU/mg
Residual TFA Volatiles ≤ 1.0%
CAS 204656-20-2
⚠ REGULATORY COMPLIANCE DIRECTIVE: INDUSTRIAL B2B SUPPLY ONLY
Shaanxi Sunrise Pharmaceutical Co., Ltd. operates strictly as an industrial active raw material and ingredient manufacturer and supplier. This product is a high-purity synthetic peptide compound intended exclusively for laboratory scientific research, non-clinical assay calibration, and generic drug formulation scale-up. Shaanxi Sunrise strictly prohibits the distribution or retail of raw materials to private individuals for direct human consumption or weight-loss clinical therapies.
Product Overview
Shaanxi Sunrise Pharmaceutical Co., Ltd. specializes in the state-of-the-art commercial manufacturing and distribution of premium-grade Liraglutide API (CAS 204656-20-2). Liraglutide is a synthetically optimized linear acylated polypeptide displaying 97% sequence homology to endogenous human Glucagon-Like Peptide-1 (GLP-1).
Our manufacturing protocols involve advanced solid-phase peptide synthesis (SPPS) loops and orthogonal liquid chromatography steps. This process ensures the complete clearance of truncated peptide fragments and chemical impurities, offering a highly consistent raw material ideal for pharmaceutical-grade research, biosimilar benchmarking, and long-acting weight management formulation scaling.
Unlike native human GLP-1, which undergoes immediate degradation by plasma enzymes within minutes, Liraglutide is molecularly engineered with an Arg34 substitution replacing Lys34 at the N-terminus, combined with the attachment of a C16 palmitoyl fatty acid side chain via a glutamic acid spacer at Lys26. This precise structural modification allows for exceptional stability and prolonged biological action.
Multi-Dimensional Pharmacological Actions
Glycemic Control Regulation
Triggers glucose-dependent insulin secretion from pancreatic beta-cells while successfully suppressing excessive postprandial glucagon release from alpha cells.
Appetite Modulation Center
Directly crosses into hypothalamic satiety centers to upregulate anorexigenic signaling, decrease hunger thresholds, and prolong gastric emptying kinetics.
Cardio-Protective Profiles
Non-clinical and comparative academic models indicate measurable vascular protective pathways, helping reduce chronic endothelial oxidative stress factors.
Pharmacokinetic Mechanism of Action
Selective Receptor Agonism: Liraglutide binds to membrane-bound GLP-1 receptors, stimulating intracellular adenylate cyclase pathways to drive glucose-dependent insulin synthesis cascades.
Reversible Albumin Binding: The engineered C-16 palmitoyl fatty acid side chain facilitates immediate, highly reversible self-association and binding to serum albumin vectors within the vascular compartment.
Proteolytic Degradation Resistance: This heavy albumin shield physically blocks dipeptidyl ppetidase-4 (DPP-4) enzymes from accessing the peptide cleavage sites, extending the systemic half-life to approximately 13 hours to support daily dosing research models.
Audited Release Specifications & Quality Parameters
| Analytical Specification Parameter | Pharmacopoeia Limit Monograph | Typical Factory Release Result | Validated Methodology |
|---|---|---|---|
| Assay Purity (Area Normalized) | ≥ 99.0% | ≥ 99.58% | Reversed-Phase HPLC (RP-HPLC) |
| Bacterial Endotoxins | ≤ 0.50 EU/mg | ≤ 0.18 EU/mg | Kinetic LAL Gel Clot Assay |
| Residual TFA Content | ≤ 1.0% | 0.45% | Ion Chromatography / GC |
| Single Maximum Impurity | ≤ 0.50% | 0.19% | HPLC Area Normalization |
| Specific Optical Rotation | -45.0° to -55.0° | -49.2° | Polarimetry Method |
| Water Content (Karl Fischer) | ≤ 5.0% | 2.8% | Titrimetric Volumetric Assay |
Technical Support & Sourcing FAQ
What establishes Shaanxi Sunrise Liraglutide API as an industry benchmark?
Our multi-stage SPPS purification loop delivers an exceptional purity profile ≥ 99.5%, minimizing background peptide deletions and clearing structural isomers. Complete batch-specific High-Performance Liquid Chromatography (HPLC) profiles and High-Resolution Mass Spectrometry (HRMS) charts are supplied for verification.
What scalable downstream packaging capacities do you fully accommodate?
We adapt seamlessly to your exact formulation cycle. For early-stage preclinical evaluations and diagnostic testing, we supply mg-scale sterile vials. For commercial compounding scale-up and bulk contract manufacturing orders, we deliver kg-scale lots packed in multi-layer vacuum-sealed aluminum bags.
How are international shipments structured to prevent multi-day thermal degradation?
Macromolecular peptide chains are highly sensitive to thermal fluctuations. To preserve the sequence's structural configuration, all overseas shipments are dispatched via specialized cold-chain pathways inside validated isothermal containers layered with dry ice or cooling packs, maintaining sub-zero parameters until destination check-in.